Incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted antibody-drug conjugates: a systematic review and meta-analysis of randomized controlled trials

被引:0
作者
Zhiwen Fu
Chen Gao
Jiyi Xie
Cong Zhang
Shijun Li
Ming Gu
Chen Shi
机构
[1] Huazhong University of Science and Technology,Department of Pharmacy, Union Hospital, Tongji Medical College
[2] Hubei Province Clinical Research Center for Precision Medicine for Critical Illness,undefined
关键词
HER2-targeted ADC; Fatal adverse events; Incidence and risk; Systematic review; Meta-analysis;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 38 条
  • [1] Korkaya H(2008)HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion Oncogene 27 6120-30
  • [2] Appert-Collin A(2015)Role of ErbB receptors in cancer cell migration and invasion Front Pharmacol 6 283-23
  • [3] Raymond E(2000)Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy Drugs 60 15-94
  • [4] Faivre S(2006)Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development Med Res Rev 26 569-25
  • [5] Armand JP(2022)Antibody drug conjugate: the “biological missile” for targeted cancer therapy Signal Transduct Target Therapy 7 1-89
  • [6] Kamath S(2021)Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial Lancet Oncol 22 779-30
  • [7] Buolamwini JK(2020)Trastuzumab Deruxtecan in previously treated HER2-Positive gastric Cancer N Engl J Med 382 2419-51
  • [8] Fu Z(2022)Trastuzumab Deruxtecan in HER2-Mutant non-small-cell Lung Cancer N Engl J Med 386 241-20
  • [9] Siena S(2022)Trastuzumab Deruxtecan in previously treated HER2-Low advanced breast Cancer N Engl J Med 387 9-54
  • [10] Shitara K(2017)Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial Lancet Oncol 18 743-95